These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
346 related articles for article (PubMed ID: 14521101)
41. Corporate imagination and expeditionary marketing. Hamel G; Prahalad CK Harv Bus Rev; 1991; 69(4):81-92. PubMed ID: 10112922 [TBL] [Abstract][Full Text] [Related]
42. Defensive marketing: how a strong incumbent can protect its position. Roberts JH Harv Bus Rev; 2005 Nov; 83(11):150-2, 154, 156-7 passim. PubMed ID: 16299967 [TBL] [Abstract][Full Text] [Related]
43. Exporting dams: China's hydropower industry goes global. McDonald K; Bosshard P; Brewer N J Environ Manage; 2009 Jul; 90 Suppl 3():S294-302. PubMed ID: 18992986 [TBL] [Abstract][Full Text] [Related]
44. Beyond the exchange--the future of B2B. Wise R; Morrison D Harv Bus Rev; 2000; 78(6):86-96. PubMed ID: 11184979 [TBL] [Abstract][Full Text] [Related]
45. Who needs budgets? Hope J; Fraser R Harv Bus Rev; 2003 Feb; 81(2):108-15,126. PubMed ID: 12577658 [TBL] [Abstract][Full Text] [Related]
46. Growing talent as if your business depended on it. Cohn JM; Khurana R; Reeves L Harv Bus Rev; 2005 Oct; 83(10):62-70, 155. PubMed ID: 16250625 [TBL] [Abstract][Full Text] [Related]
47. Will you survive the services revolution? Karmarkar U Harv Bus Rev; 2004 Jun; 82(6):100-7, 138. PubMed ID: 15202291 [TBL] [Abstract][Full Text] [Related]
48. Defining next-generation products: an inside look. Tabrizi B; Walleigh R Harv Bus Rev; 1997; 75(6):116-24. PubMed ID: 10174793 [TBL] [Abstract][Full Text] [Related]
49. Why good companies go bad. Sull DN Harv Bus Rev; 1999; 77(4):42-8, 50-2, 183. PubMed ID: 10539208 [TBL] [Abstract][Full Text] [Related]
50. The globalisation strategies of five Asian tobacco companies: a comparative analysis and implications for global health governance. Lee K; Eckhardt J Glob Public Health; 2017 Mar; 12(3):367-379. PubMed ID: 28139967 [TBL] [Abstract][Full Text] [Related]
51. Patching. Restitching business portfolios in dynamic markets. Eisenhardt KM; Brown SL Harv Bus Rev; 1999; 77(3):72-82, 208. PubMed ID: 10387579 [TBL] [Abstract][Full Text] [Related]
52. Strategy as active waiting. Sull DN Harv Bus Rev; 2005 Sep; 83(9):120-9, 160. PubMed ID: 16171216 [TBL] [Abstract][Full Text] [Related]
53. The development of China's medical biotech industry needs to be driven by innovation. Yu Z; Dai Y Biotechnol J; 2006 Nov; 1(11):1253-7. PubMed ID: 17068752 [TBL] [Abstract][Full Text] [Related]
55. From spare change to real change. The social sector as beta site for business innovation. Kanter RM Harv Bus Rev; 1999; 77(3):122-32, 210. PubMed ID: 10387574 [TBL] [Abstract][Full Text] [Related]
56. Turning negotiation into a corporate capability. Ertel D Harv Bus Rev; 1999; 77(3):55-60, 62-70, 213. PubMed ID: 10387578 [TBL] [Abstract][Full Text] [Related]
57. Smart customers, dumb companies. Locke C Harv Bus Rev; 2000; 78(6):187-91. PubMed ID: 11184973 [TBL] [Abstract][Full Text] [Related]
58. Capitalizing on capabilities. Ulrich D; Smallwood N Harv Bus Rev; 2004 Jun; 82(6):119-27, 138. PubMed ID: 15202293 [TBL] [Abstract][Full Text] [Related]
59. A buyer's guide to the innovation bazaar. Nambisan S; Sawhney M Harv Bus Rev; 2007 Jun; 85(6):109-16, 118, 142. PubMed ID: 17580653 [TBL] [Abstract][Full Text] [Related]